17.05.2024 15:25:10
|
EQS-PVR: SCHOTT Pharma AG & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: SCHOTT Pharma AG & Co. KGaA
Notification of Major Holdings
1. Details of issuer
2. Reason for notification
3. Details of person subject to the notification obligation
4. Names of shareholder(s) holding directly 3% or more voting rights, if different from 3.
5. Date on which threshold was crossed or reached:
6. Total positions
7. Details on total positions a. Voting rights attached to shares (Sec. 33, 34 WpHG)
b.1. Instruments according to Sec. 38 (1) no. 1 WpHG
b.2. Instruments according to Sec. 38 (1) no. 2 WpHG
8. Information in relation to the person subject to the notification obligation
9. In case of proxy voting according to Sec. 34 para. 3 WpHG (only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG) Date of general meeting: Holding total positions after general meeting (6.) after annual general meeting:
10. Other explanatory remarks: Date
17.05.2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | SCHOTT Pharma AG & Co. KGaA |
Hattenbergstraße 10 | |
55122 Mainz | |
Germany |
End of News | EQS News Service |
|
1906177 17.05.2024 CET/CEST
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu SCHOTT Pharmamehr Nachrichten
13.02.25 |
SCHOTT Pharma-Titel gewinnen: SCHOTT Pharma verdient weniger (dpa-AFX) | |
13.02.25 |
ROUNDUP 2: Hohe Kosten sorgen für schwächeren Jahresstart bei Schott Pharma (dpa-AFX) | |
13.02.25 |
ANALYSE-FLASH: Jefferies belässt Schott Pharma auf 'Hold' - Ziel 26,34 Euro (dpa-AFX) | |
13.02.25 |
Börse Frankfurt: Anleger lassen MDAX am Mittag steigen (finanzen.at) | |
13.02.25 |
ROUNDUP: Hohe Kosten sorgen für schwächeren Jahresstart bei Schott Pharma (dpa-AFX) | |
13.02.25 |
Optimismus in Frankfurt: MDAX präsentiert sich zum Start fester (finanzen.at) | |
13.02.25 |
Schott Pharma bestätigt trotz schwachem Jahresauftakt Prognose (Dow Jones) | |
13.02.25 |
EQS-News: SCHOTT Pharma records good start into fiscal year and confirms full year outlook (EQS Group) |
Analysen zu SCHOTT Pharmamehr Analysen
14.02.25 | SCHOTT Pharma Buy | Deutsche Bank AG | |
13.02.25 | SCHOTT Pharma Hold | Jefferies & Company Inc. | |
13.02.25 | SCHOTT Pharma Neutral | UBS AG | |
30.01.25 | SCHOTT Pharma Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
03.01.25 | SCHOTT Pharma Hold | Jefferies & Company Inc. |
Aktien in diesem Artikel
SCHOTT Pharma | 23,96 | 0,17% |
|